Rhythm Pharmaceuticals Inc
RYTM108.750USD
+2.170+2.04%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
7.25BMarket Cap
LossP/E TTM
More Details of Rhythm Pharmaceuticals Inc Company
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.
Rhythm Pharmaceuticals Inc Info
Ticker SymbolRYTM
Company nameRhythm Pharmaceuticals Inc
IPO dateOct 05, 2017
CEO- -
Number of employees283
Security typeOrdinary Share
Fiscal year-endOct 05
Address222 Berkeley Street
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02116
Phone18572644280
Websitehttps://rhythmtx.com/
Ticker SymbolRYTM
IPO dateOct 05, 2017
CEO- -
Company Executives of Rhythm Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
--
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
7.00K
+133.33%
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Independent Director
Independent Director
7.00K
+133.33%
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Alastair (Al) Garfield, Ph.D.
Dr. Alastair (Al) Garfield, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
201.82K
--
Mr. Hunter C. Smith
Mr. Hunter C. Smith
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.92K
--
Mr. Yann Mazabraud
Mr. Yann Mazabraud
Executive Vice President, Head of International
Executive Vice President, Head of International
37.66K
-6.73%
Mr. Joseph (Joe) Shulman
Mr. Joseph (Joe) Shulman
Chief Technical Officer
Chief Technical Officer
8.51K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
Independent Director
Independent Director
7.00K
+133.33%
Mr. Christophe R. Jean
Mr. Christophe R. Jean
Independent Director
Independent Director
7.00K
+133.33%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
96.11M
73.86%
International
34.02M
26.14%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
8.51%
Baker Bros. Advisors LP
8.40%
The Vanguard Group, Inc.
7.47%
PRIMECAP Management Company
6.39%
BlackRock Institutional Trust Company, N.A.
5.88%
Other
63.35%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
8.51%
Baker Bros. Advisors LP
8.40%
The Vanguard Group, Inc.
7.47%
PRIMECAP Management Company
6.39%
BlackRock Institutional Trust Company, N.A.
5.88%
Other
63.35%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.63%
Investment Advisor/Hedge Fund
30.37%
Hedge Fund
15.95%
Venture Capital
13.66%
Research Firm
4.00%
Private Equity
3.98%
Bank and Trust
0.75%
Individual Investor
0.67%
Pension Fund
0.44%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
461
70.26M
105.28%
-843.23K
2025Q2
451
66.54M
100.20%
-6.36M
2025Q1
464
66.24M
104.13%
-6.91M
2024Q4
438
66.17M
104.69%
-7.75M
2024Q3
414
68.98M
112.28%
-7.86M
2024Q2
402
70.62M
115.59%
-5.66M
2024Q1
385
68.75M
112.78%
-8.84M
2023Q4
369
67.33M
113.30%
-8.52M
2023Q3
350
68.72M
116.31%
-2.96M
2023Q2
327
67.69M
118.97%
+564.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
5.56M
8.37%
-523.05K
-8.60%
Jun 30, 2025
Baker Bros. Advisors LP
5.60M
8.44%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
5.39%
+144.19K
+4.20%
Jun 30, 2025
PRIMECAP Management Company
4.88M
7.34%
-909.28K
-15.71%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.91M
5.88%
-93.66K
-2.34%
Jun 30, 2025
New Enterprise Associates (NEA)
2.91M
4.38%
--
--
Jun 30, 2025
Perceptive Advisors LLC
2.42M
3.64%
-130.15K
-5.11%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.91M
2.87%
+272.55K
+16.66%
Jun 30, 2025
State Street Investment Management (US)
1.91M
2.87%
-63.13K
-3.20%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.60M
2.41%
+37.94K
+2.43%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Innovator IBD 50 Fund ETF
4.21%
ALPS Medical Breakthroughs ETF
4.11%
Virtus LifeSci Biotech Products ETF
2.67%
Harbor Human Capital Factor US Small Cap ETF
1.97%
Roundhill GLP-1 & Weight Loss ETF
1.88%
Harbor Health Care ETF
1.8%
iShares Health Innovation Active ETF
1.79%
Invesco Dorsey Wright Healthcare Momentum ETF
1.5%
SPDR S&P Biotech ETF
1.45%
First Trust Multi-Manager Small Cap Opportunities ETF
0.76%
View more
Innovator IBD 50 Fund ETF
Proportion4.21%
ALPS Medical Breakthroughs ETF
Proportion4.11%
Virtus LifeSci Biotech Products ETF
Proportion2.67%
Harbor Human Capital Factor US Small Cap ETF
Proportion1.97%
Roundhill GLP-1 & Weight Loss ETF
Proportion1.88%
Harbor Health Care ETF
Proportion1.8%
iShares Health Innovation Active ETF
Proportion1.79%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.5%
SPDR S&P Biotech ETF
Proportion1.45%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.76%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Rhythm Pharmaceuticals Inc?
The top five shareholders of Rhythm Pharmaceuticals Inc are:
RA Capital Management, LP holds 5.56M shares, accounting for 8.37% of the total shares.
Baker Bros. Advisors LP holds 5.60M shares, accounting for 8.44% of the total shares.
The Vanguard Group, Inc. holds 3.58M shares, accounting for 5.39% of the total shares.
PRIMECAP Management Company holds 4.88M shares, accounting for 7.34% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.91M shares, accounting for 5.88% of the total shares.
RA Capital Management, LP holds 5.56M shares, accounting for 8.37% of the total shares.
Baker Bros. Advisors LP holds 5.60M shares, accounting for 8.44% of the total shares.
The Vanguard Group, Inc. holds 3.58M shares, accounting for 5.39% of the total shares.
PRIMECAP Management Company holds 4.88M shares, accounting for 7.34% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.91M shares, accounting for 5.88% of the total shares.
What are the top three shareholder types of Rhythm Pharmaceuticals Inc?
The top three shareholder types of Rhythm Pharmaceuticals Inc are:
RA Capital Management, LP
Baker Bros. Advisors LP
The Vanguard Group, Inc.
RA Capital Management, LP
Baker Bros. Advisors LP
The Vanguard Group, Inc.
How many institutions hold shares of Rhythm Pharmaceuticals Inc (RYTM)?
As of 2025Q3, 461 institutions hold shares of Rhythm Pharmaceuticals Inc, with a combined market value of approximately 70.26M, accounting for 105.28% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 5.08%.
What is the biggest source of revenue for Rhythm Pharmaceuticals Inc?
In FY2024, the -- business generated the highest revenue for Rhythm Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
